Vertex Shrugs Off Recent Malaise With A Third-Quarter Beat-And-Raise

Vertex Pharmaceuticals (VRTX) beat third-quarter expectations, helping VRTX stock surge on Friday.

On today's stock market, VRTX stock advanced 9% to 313.89. Shares fell about 7.5% during Thursday's regular session. It was unclear what drove the dive, though it could possibly be related to an upcoming presentation from 4D Molecular Therapeutics (FDMT) for a cystic fibrosis treatment.